|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||8.70 / 19.96|
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Insys Therapeutics, Inc.
Insys Therapeutics, Ultragenyx Pharmaceutical and Alexion Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.
Investors in Insys Therapeutics Inc saw new options begin trading this week, for the November 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Insys Therapeutics, Inc.
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Insys Therapeutics, Inc.
Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Insys Therapeutics, Inc.
Shares of Insys Therapeutics INSY tumbled Thursday after the company revealed that it would be reporting fourth quarter earnings later than expected thanks to delays from its audit committee.
Levi & Korsinsky announces it has commenced an investigation of INSYS Therapeutics, Inc.
-- Fourth Quarter 2016 Net Sales Estimated at $54 million --
These heavily shorted stocks could get squeezed higher if they report positive earnings this week.
The most recent short interest data has been released for the 02/28/2017 settlement date, which shows a 2,019,716 share decrease in total short interest for Insys Therapeutics Inc , to 11,726,537, a decrease of 14.69% since 02/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
In trading on Wednesday, shares of Insys Therapeutics Inc crossed above their 200 day moving average of $12.92, changing hands as high as $13.56 per share. Insys Therapeutics Inc shares are currently trading up about 6.7% on the day.
The timing of Schwartz' exit is noteworthy given Galena's admission on Jan. 9 of a criminal investigation of the company by the federal prosecutors into the marketing of Abstral.
Cannabis stocks are not affected by the volatility in prices during earnings season and instead trade on positive data such as potential FDA approval on their pipeline of drugs.
Investors in Insys Therapeutics Inc saw new options begin trading this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new March 17th contracts and identified one put and one call contract of particular interest.